US Patent

US8895557 — Pharmaceutical formulations of ecteinascidin compounds

Formulation · Assigned to Pharmamar SA · Expires 2028-01-07 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical formulations of ecteinascidin compounds, including Yondelis, and methods for preparing and using them to treat proliferative diseases.

USPTO Abstract

Ecteinascidin formulations, methods of preparing the same, articles of manufacture and kits with such formulations, and methods of treating proliferative diseases with the same formulations are provided.

Drugs covered by this patent

Yondelis (TRABECTEDIN) · Janssen Prods

Patent Metadata

Patent number: US8895557
Jurisdiction: US
Classification: Formulation
Expires: 2028-01-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Pharmamar SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.